MedTrace Logo

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

NCT00088621 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2014-04-17

Study results available
· View outcomes & findings →

Summary

A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia

Conditions

Interventions

DRUG

Lurasidone 80mg tablet

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Sumitomo Pharma America, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088621 on ClinicalTrials.gov